Decreased renal function does not change the single-dose pharmacokinetics for metronidazole. Subjects with ESRD had no significant change in pharmacokinetics, but had higher Cmax of metabolites ...
Decreased renal function does not change the single-dose pharmacokinetics for metronidazole. Subjects with ESRD had no significant change in pharmacokinetics, but had higher Cmax of metabolites ...
Approximately 5% to 10% of women with IAI will develop bacteremia. [10] Other maternal complications include labor abnormalities, increased need for oxytocin, and increased risk of cesarean birth.